{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:38:17Z","timestamp":1792420697106,"version":"4.5.0"},"reference-count":58,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Cytomegalovirus (CMV) colitis, a complication in patients with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), is a significant diagnostic and therapeutic challenge due to its overlap with IBD flares. CMV reactivation in IBD is driven by chronic inflammation, compromised immune function, and use of immunosuppressive agents like corticosteroids. Risk factors include older age, pancolitis, and severe disease. Diagnosis hinges on endoscopy and histology, with tissue biopsy and immunohistochemistry as the gold standard. Quantitative tissue PCR may aid in differentiating latent from active infection. CMV colitis exacerbates IBD symptoms, prolongs hospitalization, and increases colectomy rates. Antiviral therapy, primarily ganciclovir, improves outcomes in patients with corticosteroid-refractory UC. Treatment focuses on tapering corticosteroids, optimizing biologic therapies such as infliximab, and a careful application of antivirals tailored to disease severity and viral load. Further research is needed to refine diagnostic thresholds and treatment strategies to mitigate CMV\u2019s impact on IBD prognosis. Early identification and individualized management are critical to improving clinical outcomes and reducing morbidity.<\/jats:p>","DOI":"10.3390\/v17060752","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T20:39:36Z","timestamp":1748205576000},"page":"752","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"17","author":[{"given":"Kriti","family":"Soni","sequence":"first","affiliation":[{"name":"Government Medical College and Hospital, Chandigarh 160047, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9836-4835","authenticated-orcid":false,"given":"Alfredo","family":"Puing","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Yale University, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e29525","DOI":"10.1002\/jmv.29525","article-title":"Estimated cytomegalovirus seroprevalence in the general population of the United States and Canada","volume":"96","author":"Flanders","year":"2024","journal-title":"J. Med. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","article-title":"Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments","volume":"4","author":"Gandhi","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1128\/microbiolspec.DMIH2-0022-2015","article-title":"Cytomegalovirus","volume":"4","author":"Dioverti","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/j.1572-0241.2006.00869.x","article-title":"Cytomegalovirus colitis complicating inflammatory bowel disease","volume":"101","author":"Kandiel","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J. Crohns Colitis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.29271\/jcpsp.2020.10.1015","article-title":"Opportunistic infection in hospitalised patients with inflammatory bowel disease","volume":"30","author":"Zhou","year":"2020","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Shimada, T., Higashida-Konishi, M., Izumi, K., Hama, S., Oshige, T., Oshima, H., and Okano, Y. (2022). Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: A retrospective study. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-25451-4"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1099\/jmm.0.45629-0","article-title":"Infection with cytomegalovirus in patients with inflammatory bowel disease: Prevalence, clinical significance and outcome","volume":"53","author":"Kishore","year":"2004","journal-title":"J. Med. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Qin, Y., Wang, G., Kong, D., Li, G., Wang, H., Qin, H., and Wang, H. (2021). Risk factors of cytomegalovirus reactivation in ulcerative colitis patients: A meta-analysis. Diagnostics, 11.","DOI":"10.3390\/diagnostics11111952"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4253\/wjge.v8.i6.301","article-title":"Characteristic endoscopic findings and risk factors for cytomegalovirus-associated colitis in patients with active ulcerative colitis","volume":"8","author":"Hirayama","year":"2016","journal-title":"World J. Gastrointest. Endosc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/MIB.0000000000000675","article-title":"Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe ulcerative colitis","volume":"22","author":"Lee","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hsieh, C.-R., Wu, R.-C., Kuo, C.-J., Yeh, P.-J., Yeh, Y.-M., Chen, C.-L., Chiu, C.-H., Pan, Y.-B., Tsou, Y.-K., and Le, P.-H. (2024). Adequate antiviral treatment lowers overall complications of cytomegalovirus colitis among inpatients with inflammatory bowel diseases. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09317-w"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4103\/sjmms.sjmms_175_23","article-title":"Prevalence and risk factors of cytomegalovirus colitis in inflammatory bowel disease patients in Riyadh, Saudi Arabia: A tertiary center experience","volume":"11","author":"Alotaibi","year":"2023","journal-title":"Saudi J. Med. Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","article-title":"Mechanisms of disease: Inflammatory bowel diseases","volume":"94","author":"Ramos","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Jentzer, A., Veyrard, P., Roblin, X., Saint-Sardos, P., Rochereau, N., Paul, S., Bourlet, T., Pozzetto, B., and Pillet, S. (2020). Cytomegalovirus and inflammatory bowel diseases (IBD) with a special focus on the link with ulcerative colitis (UC). Microorganisms, 8.","DOI":"10.3390\/microorganisms8071078"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/314602","article-title":"Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients","volume":"179","author":"Humar","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Maidji, E., Somsouk, M., Rivera, J.M., Hunt, P.W., and Stoddart, C.A. (2017). Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006202"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: Current state of the art","volume":"13","author":"Fiocchi","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbrc.2015.01.091","article-title":"Glucocorticoids facilitate the transcription from the human cytomegalovirus major immediate early promoter in glucocorticoid receptor- and nuclear factor-I-like protein-dependent manner","volume":"458","author":"Kato","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1099\/vir.0.069872-0","article-title":"Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D + R + liver transplant patients","volume":"96","author":"Sauviller","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1155\/2003\/824547","article-title":"6-mercaptopurine and inflammatory bowel disease: Hidden ground for the cytomegalovirus","volume":"17","author":"Hookey","year":"2003","journal-title":"Can. J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MCG.0000000000000758","article-title":"Corticosteroids and thiopurines, but not tumor necrosis factor antagonists, are associated with cytomegalovirus reactivation in inflammatory bowel disease: A systematic review and meta-analysis","volume":"51","author":"Shukla","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/imj.15085","article-title":"Cytomegalovirus in inflammatory bowel disease: A clinical approach","volume":"52","author":"Gilmore","year":"2022","journal-title":"Intern. Med. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcv.2015.03.009","article-title":"Toxic megacolon and human cytomegalovirus in a series of severe ulcerative colitis patients","volume":"66","author":"Criscuoli","year":"2015","journal-title":"J. Clin. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.5009\/gnl13427","article-title":"Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: A multicenter study","volume":"8","author":"Kim","year":"2014","journal-title":"Gut Liver"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3748\/wjg.v16.i10.1245","article-title":"Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection","volume":"16","author":"Suzuki","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1080\/00365521.2019.1646798","article-title":"True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: The 10-year experience of an academic referral inflammatory bowel disease center","volume":"54","author":"Oh","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"20406223241233203","DOI":"10.1177\/20406223241233203","article-title":"Impact of cytomegalovirus on outcomes in acute severe ulcerative colitis: A retrospective observational study","volume":"15","author":"Huang","year":"2024","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.3892\/etm.2016.3763","article-title":"Effects of cytomegalovirus infection on the prognosis of inflammatory bowel disease patients","volume":"12","author":"Zhang","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1007\/s10620-015-3733-6","article-title":"Relationship between cytomegalovirus infection and steroid resistance in inflammatory bowel disease: A meta-analysis","volume":"60","author":"Wu","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MIB.0000000000001073","article-title":"Diagnostic accuracy of blood-based tests and histopathology for cytomegalovirus reactivation in inflammatory bowel disease: A systematic review and meta-analysis","volume":"23","author":"Tandon","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1097\/MIB.0000000000000556","article-title":"Detection of cytomegalovirus in patients with inflammatory bowel disease: Where to biopsy and how many biopsies?","volume":"21","author":"McCurdy","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1086\/599116","article-title":"Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease","volume":"48","author":"Jang","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gentile, G., Picardi, A., Capobianchi, A., Spagnoli, A., Cudillo, L., Dentamaro, T., Tendas, A., Cupelli, L., Ciotti, M., and Volpi, A. (2006). A prospective study comparing quantitative cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Infect. Dis., 6.","DOI":"10.1186\/1471-2334-6-167"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e249891","DOI":"10.1136\/bcr-2022-249891","article-title":"Cytomegaloviral colitis in primary CMV viraemia in a young immunocompetent adult","volume":"15","author":"King","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e01500","DOI":"10.1016\/j.idcr.2022.e01500","article-title":"Cytomegalovirus colitis in an immunocompromised patient presenting with massive lower gastrointestinal bleeding","volume":"28","author":"Surapatpichai","year":"2022","journal-title":"IDCases"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.34172\/aim.2024.40","article-title":"Cytomegalovirus infection in adult patients with inflammatory bowel disease: A literature review","volume":"27","author":"Sanat","year":"2024","journal-title":"Arch. Iran Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, H. (2024). Practical updates in clinical antiviral resistance testing. J. Clin. Microbiol., 62.","DOI":"10.1128\/jcm.00728-23"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1572-0241.2006.00989.x","article-title":"Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients","volume":"102","author":"Matsuoka","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/MEG.0000000000000175","article-title":"Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: Effect of antiviral treatment","volume":"26","author":"Maconi","year":"2014","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1038\/ctg.2016.10","article-title":"Cytomegalovirus-related hospitalization is associated with adverse outcomes and increased health-care resource utilization in inflammatory bowel disease","volume":"7","author":"Zhang","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.cgh.2014.09.042","article-title":"Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus","volume":"13","author":"Jones","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1097\/MIB.0000000000000489","article-title":"Antiviral therapy in steroid-refractory ulcerative colitis with cytomegalovirus: Systematic review and meta-analysis","volume":"21","author":"Shukla","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1097\/MIB.0000000000000412","article-title":"Infliximab does not worsen outcomes during flare-ups associated with cytomegalovirus infection in patients with ulcerative colitis","volume":"21","author":"Pillet","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3748\/wjg.v13.i5.754","article-title":"Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan","volume":"13","author":"Minami","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/ecco-jcc\/jjz033","article-title":"Resolution of CMV infection in the bowel on vedolizumab therapy","volume":"13","author":"Lenarcik","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/ecco-jcc\/jjz108","article-title":"Comment on: \u2018Resolution of CMV infection in the bowel on vedolizumab therapy\u2019","volume":"14","author":"Hommel","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.14309\/01.ajg.0000776456.24856.73","article-title":"S731 Cytomegalovirus colitis is rarely observed after initiation of infliximab, adalimumab, or vedolizumab in biologic-na\u00efve patients with ulcerative colitis","volume":"116","author":"Dalal","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_51","first-page":"e35439","article-title":"Cytomegalovirus colitis in a patient with ulcerative colitis on vedolizumab monotherapy","volume":"15","author":"Meeralam","year":"2023","journal-title":"Cureus"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s10620-019-05492-y","article-title":"Real-world experience with tofacitinib in IBD at a tertiary center","volume":"64","author":"Weisshof","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of ustekinumab in inflammatory bowel disease: Pooled safety analysis of results from phase 2\/3 studies","volume":"27","author":"Sandborn","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/ecco-jcc\/jjw071","article-title":"Cytomegalovirus infection in ulcerative colitis is related to severe inflammation and a high count of cytomegalovirus-positive cells in biopsy is a risk factor for colectomy","volume":"10","author":"Bugajski","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"11785","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl. Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J. Crohns Colitis"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/6\/752\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:39:53Z","timestamp":1760031593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/6\/752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["v17060752"],"URL":"https:\/\/doi.org\/10.3390\/v17060752","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]}}}